Merck’s Ebola vaccine authorised by the US FDA

After long awaited approval, Merck & Co’s (MRK) Ebola virus disease (EVD) vaccine, Ervebo, has finally been authorised by the Food and Drug Administration. The Ebola vaccine, which was used by the World Health Organisation and Democratic Republic of the Congo to decrease the extreme outbreak of Ebola disease on patients in West Africa between 2014/16, is the first-ever Ebola vaccine in the entire history, to be approved by the FDA and will only be provided to adults in a single dose.